Pacira BioSciences (PCRX) Stock Chart & Stock Price History $14.54 +0.21 (+1.47%) (As of 09/27/2024 ET) Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Pacira BioSciences Stock Price Performance5 Day Performance+1.96%1 Month Performance-5.34%3 Month Performance-49.18%6 Month Performance-50.24%Year-To-Date Performance-56.91%1 Year Performance-52.61% Receive PCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter Email Address Ad Behind the MarketsThe $15 Stock Powering NVIDIA, TESLA and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known supplier, which provides a crucial building block for AI.Click here for the ticker >>> PCRX Stock Chart for Sunday, September, 29, 2024 PCRX Chart by TradingView Pacira BioSciences Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization09/27/2024$14.33$14.54+1.47%$14.75$14.19632,728 shs$676.78 million09/26/2024$13.91$14.33+3.02%$14.60$13.89625,565 shs$661.04 million09/25/2024$14.26$13.91-2.45%$14.94$13.791.22 million shs$641.67 million09/24/2024$14.28$14.26-0.14%$14.83$14.201.23 million shs$663.75 million09/23/2024$14.53$14.28-1.72%$14.59$13.931.15 million shs$664.68 million09/20/2024$14.69$14.53-1.09%$15.15$14.484.30 million shs$676.31 million Get the Latest News and Ratings for PCRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter. 09/19/2024$14.65$14.69+0.27%$15.23$14.50897,974 shs$683.76 million09/18/2024$14.35$14.65+2.13%$15.22$14.11952,980 shs$681.90 million09/17/2024$13.49$14.35+6.34%$14.56$13.42983,485 shs$667.70 million09/16/2024$13.11$13.49+2.90%$13.90$13.041.98 million shs$587.20 million09/13/2024$12.73$13.11+2.99%$13.27$12.84886,159 shs$604.76 million09/12/2024$13.00$12.73-2.08%$13.23$12.611.07 million shs$592.53 million09/11/2024$13.25$13.00-1.89%$13.44$12.851.00 million shs$599.69 million09/10/2024$13.23$13.25+0.15%$13.66$13.191.13 million shs$611.22 million09/09/2024$13.85$13.23-4.48%$14.06$13.111.11 million shs$610.30 million09/06/2024$14.68$13.85-5.65%$14.90$13.77884,129 shs$638.90 million09/05/2024$15.14$14.68-3.04%$15.36$14.64645,373 shs$677.19 million09/04/2024$15.18$15.14-0.26%$15.59$15.061.34 million shs$717.73 million09/03/2024$15.56$15.18-2.44%$15.73$15.14920,713 shs$706.57 million09/02/2024$15.56$15.56$15.80$15.29702,200 shs$717.78 million08/30/2024$15.36$15.56+1.30%$15.80$15.29702,297 shs$724.26 million08/29/2024$14.90$15.36+3.09%$15.57$14.95840,948 shs$714.95 million08/28/2024$14.48$14.90+2.90%$14.97$14.37811,516 shs$693.54 million08/27/2024$14.48$14.48$14.71$14.32656,437 shs$673.99 million08/26/2024$14.19$14.48+2.04%$14.57$13.98985,178 shs$673.99 million08/23/2024$13.97$14.19+1.57%$14.40$13.881.04 million shs$654.59 million08/22/2024$13.85$13.97+0.87%$13.99$13.591.13 million shs$596.88 million08/21/2024$13.89$13.85-0.29%$14.03$13.78931,564 shs$644.66 million08/20/2024$13.98$13.89-0.64%$14.00$13.581.19 million shs$640.75 million08/19/2024$12.94$13.98+8.04%$14.04$13.071.61 million shs$644.90 million08/16/2024$13.35$12.94-3.07%$13.35$12.771.50 million shs$596.92 million08/15/2024$12.47$13.35+7.06%$13.42$12.761.85 million shs$615.84 million08/14/2024$12.40$12.47+0.56%$12.90$12.151.83 million shs$580.43 million08/13/2024$12.29$12.40+0.90%$12.75$11.164.31 million shs$577.17 million08/12/2024$11.70$12.29+5.04%$12.88$11.266.89 million shs$572.05 million08/09/2024$22.36$11.70-47.67%$24.00$11.703.25 million shs$544.59 million08/08/2024$22.33$22.36+0.13%$22.82$22.15557,153 shs$1.04 billion08/07/2024$21.61$22.33+3.33%$22.40$21.731.01 million shs$1.04 billion08/06/2024$20.18$21.61+7.09%$21.89$20.061.12 million shs$996.87 million08/05/2024$21.26$20.18-5.08%$20.54$19.75577,608 shs$930.90 millionEx-Wall Street CEO reveals “Millionaire-Maker” Superdrug (Ad)Science Magazine called it the "breakthrough of the year"... With projections of 8,966% growth in the next four years.Click here for our #1 "Retirement Window" Stock >>>08/02/2024$20.75$21.26+2.46%$21.39$19.98942,335 shs$980.72 million08/01/2024$20.65$20.75+0.48%$21.25$20.23743,092 shs$965.91 million07/31/2024$19.54$20.65+5.68%$22.88$20.321.53 million shs$961.26 million07/30/2024$20.36$19.54-4.00%$20.54$19.49978,842 shs$909.59 million07/29/2024$20.03$20.36+1.62%$20.44$19.67833,586 shs$947.53 million07/26/2024$19.98$20.03+0.25%$20.58$19.94973,328 shs$932.40 million07/25/2024$20.26$19.98-1.38%$20.40$19.681.47 million shs$930.07 million07/24/2024$19.98$20.26+1.40%$20.42$19.701.41 million shs$943.10 million07/23/2024$20.21$19.98-1.14%$20.20$19.63927,372 shs$930.07 million07/22/2024$19.37$20.21+4.34%$20.35$19.521.17 million shs$940.78 million07/19/2024$20.22$19.37-4.20%$20.58$19.341.06 million shs$901.60 million07/18/2024$20.99$20.22-3.67%$21.69$20.001.49 million shs$941.24 million07/17/2024$21.37$20.99-1.78%$21.76$20.661.10 million shs$977.08 million07/16/2024$21.30$21.37+0.33%$21.80$20.921.44 million shs$994.77 million07/15/2024$21.76$21.30-2.11%$22.13$21.151.46 million shs$991.52 million07/12/2024$21.81$21.76-0.23%$22.31$21.28945,479 shs$1.01 billion07/11/2024$20.34$21.81+7.23%$21.83$20.501.01 million shs$1.02 billion07/10/2024$20.96$20.34-2.96%$21.19$20.08858,174 shs$946.83 million07/09/2024$20.60$20.96+1.75%$21.66$20.251.04 million shs$975.69 million07/08/2024$21.06$20.60-2.18%$21.26$20.521.14 million shs$958.93 million07/05/2024$21.66$21.06-2.77%$21.59$20.821.19 million shs$980.26 million07/04/2024$21.66$21.66$22.57$21.411.04 million shs$1.01 billion07/03/2024$22.74$21.66-4.75%$22.57$21.411.04 million shs$1.01 billion07/02/2024$28.46$22.74-20.10%$28.63$20.529.12 million shs$1.06 billion07/01/2024$28.61$28.46-0.52%$29.33$28.45728,004 shs$1.32 billion06/28/2024$27.91$28.61+2.51%$28.95$27.892.31 million shs$1.33 billion Related Companies: OPKO Health Stock Chart Atea Pharmaceuticals Stock Chart ADC Therapeutics Stock Chart Seres Therapeutics Stock Chart Supernus Pharmaceuticals Stock Chart Omeros Stock Chart Nektar Therapeutics Stock Chart Assembly Biosciences Stock Chart Cumberland Pharmaceuticals Stock Chart Alkermes Stock Chart Receive PCRX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:PCRX) was last updated on 9/29/2024 by MarketBeat.com Staff From Our PartnersThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This pa...Prosperity Research | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the ...Porter & Company | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.